Portal de Periódicos da CAPES

SAW PALMETTO FOR THE TREATMENT OF MEN WITH LOWER URINARY TRACT SYMPTOMS

2000; Lippincott Williams & Wilkins; Volume: 163; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)67631-8

1527-3792

Glenn S. Gerber,

Dermatology and Skin Diseases

No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 May 2000SAW PALMETTO FOR THE TREATMENT OF MEN WITH LOWER URINARY TRACT SYMPTOMS GLENN S. GERBER GLENN S. GERBERGLENN S. GERBER View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67631-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A comprehensive review of the literature on the use of saw palmetto in men with lower urinary tract symptoms is provided. Materials and Methods: A literature search of studies that have assessed the mechanism of action and clinical results of saw palmetto in men with benign prostatic hyperplasia was performed. Results: A variety of potential mechanisms of action of saw palmetto have been demonstrated through in vitro studies, including 5-α reductase inhibition, adrenergic receptor antagonism and intraprostatic androgen receptor blockade. Clinical evidence of the relevance of these effects is largely unavailable. The use of saw palmetto in men with benign prostatic hyperplasia is safe with no recognized adverse effects. No effect on serum prostate specific antigen has been noted. Placebo controlled trials and meta-analyses have suggested that saw palmetto leads to subjective and objective improvement in men with lower urinary tract symptoms. However, most studies are significantly limited by methodological flaws, small patient numbers and brief treatment intervals. Conclusions: Evidence suggests that saw palmetto may have a significant effect on urinary flow rates and symptom scores compared to placebo in men with lower urinary tract symptoms. However, large scale, placebo controlled trials are needed to assess the efficacy of saw palmetto. References 1 : Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med1993; 328: 246. Google Scholar 2 : Growing use of medicinal botanicals forces assessment by drug regulators. JAMA1995; 273: 607. Google Scholar 3 : Harmless herbs? A review of the recent literature. Am J Med1998; 104: 170. Google Scholar 4 : Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA1998; 280: 1604. Google Scholar 5 Int Med World Report1998; 13: 8. Google Scholar 6 : Why patients use alternative medicine: results of a national study. JAMA1998; 279: 1548. Google Scholar 7 : Why do patients turn to complementary medicine? An empirical study. Br J Clin Psychol1996; 35: 37. Google Scholar 8 : The attitudes, behaviors, and beliefs of patients of conventional vs. complementary (alternative) medicine. J Clin Psychol1994; 50: 458. Google Scholar 9 : Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology1996; 48: 12. Google Scholar 10 : Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology1999; 54: 86. Google Scholar 11 : Alternative medicine—the risks of untested and unregulated remedies. N Engl J Med1998; 339: 839. Google Scholar 12 : Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med1998; 339: 785. Google Scholar 13 : Modification of the effect of tamoxifen, cisplatin, DTIC, and interferon-alpha2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer1994; 22: 233. Google Scholar 14 : Butyrolactone-induced central nervous system depression after ingestion of RenewTrient, a "dietary supplement". N Engl J Med1998; 339: 847. Google Scholar 15 : Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate1998; 37: 187. Google Scholar 16 : Phytotherapy for the prostate. Br J Urol1996; 78: 325. Google Scholar 17 : Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol1998; 81: 383. Google Scholar 18 : The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol1997; 157: 10. Link, Google Scholar 19 : Editorial Comment. Urology1998; 51: 1007. Google Scholar 20 : Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology1998; 51: 1003. Google Scholar 21 : . New Canaan, Connecticut: Keats Publishing1993: 355. Google Scholar 22 : What do commercial ginseng preparations contain?. Lancet1994; 344: 134. Google Scholar 23 : Serenoa repens (Permixon). A review of is pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging1996; 9: 379. Google Scholar 24 : Plant extracts in BPH. Minerva Urol Nefrol1993; 45: 143. Google Scholar 25 : Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. Prostate1996; 29: 231. Google Scholar 26 : Human prostatic steroid 5 alpha-reductase isoforms—a comparative study of selective inhibitors. J Steroid Biochem Mol Biol1995; 54: 273. Google Scholar 27 : Steroid 5-alpha-reductase: two genes/two enzymes. Ann Rev Biochem1994; 63: 25. Google Scholar 28 : Selectivity of finasteride as an in vivo inhibitor of 5-alpha reductase isozyme enzymatic activity in the human prostate. J Urol1999; 161: 332. Link, Google Scholar 29 : The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med1992; 327: 1185. Google Scholar 30 : Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate1993; 22: 43. Google Scholar 31 : Tissue distribution and ontogeny of steroid 5-alpha reductase isozyme expression. J Clin Invest1993; 92: 903. Google Scholar 32 : Kinetic analysis of steroid 5-alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. J Steroid Biochem Mol Biol1996; 57: 103. Google Scholar 33 : Immunohistochemical analysis of steroid 5-alpha-reductase type 1 in human scalp and prostate. Ann NY Acad Sci1996; 784: 27. Google Scholar 34 : Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate1996; 28: 300. Google Scholar 35 : Inhibition of human prostatic testosterone metabolism by a lipido-sterol extract of Serenoa repens (Permixon). J Urol1996; 155: 572A. abstract 1046. Google Scholar 36 : Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol1994; 26: 247. Google Scholar 37 : Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate1998; 37: 77. Google Scholar 38 : Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem1984; 20: 515. Google Scholar 39 : Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem1984; 20: 521. Google Scholar 40 : Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate1996; 29: 219. Google Scholar 41 : Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res1996; 34: 171. Google Scholar 42 : Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther1988; 10: 585. Google Scholar 43 : Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol1992; 21: 309. Google Scholar 44 : The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci1995; 2: 357. Google Scholar 45 : Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol1998; 33: 340. Google Scholar 46 : Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids1997; 57: 299. Google Scholar 47 : Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol (Copenh)1981; 96: 422. Google Scholar 48 : Saw palmetto extracts potently and noncompetitively inhibit human alpha-1-adrenoceptors in vitro. Prostate1999; 38: 208. Google Scholar 49 : Kombination aus Sabal-und urticaextrakt vs. finasterid bei BPH (Stad. I bis II nach alken). Urologe A1997; 36: 327. Google Scholar 50 : Tratamiento sintomatico de la hipertrofia benigna de prostata. Estudio comparativo entre prazosin y Serenoa repens. Arch Esp Urol1992; 45: 211. Google Scholar 51 : Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol1995; 48: 97. Google Scholar 52 Chopin, D., Perier, A. and Raynaud, J. P.: Improvements in benign prostatic hypertrophy (BPH) symptoms are not related to prostatic volume in the Permixon/finasteride comparative study. Presented at the 4th International Consultation on BPH, Paris, France, 1997 Google Scholar 53 : The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res1994; 55: 776. Google Scholar 54 : Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest1995; 9: 291. Google Scholar 55 : The value of Permixon in benign prostatic hypertrophy. Br J Urol1986; 58: 36. Google Scholar 56 : A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmac1984; 18: 461. Google Scholar 57 : Traitement medical de l'adenome prostatique. Ann Urol (Paris)1984; 18: 407. Google Scholar 58 : Confronto fra estratto di Serenoa repens e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. Urologia1983; 50: 1. Google Scholar 59 : Wirdsamkeit eines Sabal-urtica-kombinationspraparats bei der behandlung der benignen prostathyperplasie (BPH). Urologe B1996; 36: 292. Google Scholar 60 : Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Minerva Urol Nefrol1985; 37: 87. Google Scholar 61 : Permixon versus placebo Results d'une etude multicentrique. C R Ther Pharmacol Clin1985; 4: 15. Google Scholar 62 : Risultati clinic su un nuovo farmaco nelle terapia dell'ipertrofia della prostate (Permixon). Urologia1983; 50: 1042. Google Scholar 63 : Meta-analysis of clinical trials of Permixon. J Urol1998; 159: 257. abstract 986. Google Scholar 64 Roehrborn, C. G.: BPH Clinical Research Criteria. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), 1997. Roehrborn, C G. BPH Clinical Research Criteria. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). 437-514, 1997 Google Scholar 65 : The promise and problems of meta-analysis. N Engl J Med1997; 337: 559. Google Scholar 66 : The practice of meta-analysis. J Clin Epidemiol1995; 48: 149. Google Scholar 67 : Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med1997; 337: 536. Google Scholar 68 : Is meta-analysis a valid approach to the evaluation of small effects in observational studies. J Clin Epidemiol1997; 50: 223. Google Scholar 69 Dreikorn, K., Borkowski, A., Braeckman, J. et al: Other medical therapies. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), 1997. Dreikorn, K. Borkowski, A. Braeckman, J. Other medical therapies. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH) 633-659, 1997 Google Scholar From the Section of Urology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKaplan S (2018) Re: Comparison of Tamsulosin plus Serenoa repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label StudyJournal of Urology, VOL. 196, NO. 2, (503-503), Online publication date: 1-Aug-2016.Andriole G, McCullum-Hill C, Sandhu G, Crawford E, Barry M and Cantor A (2018) The Effect of Increasing Doses of Saw Palmetto Fruit Extract on Serum Prostate Specific Antigen: Analysis of the CAMUS Randomized TrialJournal of Urology, VOL. 189, NO. 2, (486-492), Online publication date: 1-Feb-2013.Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A and Rao J (2018) Effect of Saw Palmetto Soft Gel Capsule on Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized Trial in Shanghai, ChinaJournal of Urology, VOL. 179, NO. 2, (610-615), Online publication date: 1-Feb-2008.BUCK A (2018) IS THERE A SCIENTIFIC BASIS FOR THE THERAPEUTIC EFFECTS OF SERENOA REPENS IN BENIGN PROSTATIC HYPERPLASIA? MECHANISMS OF ACTIONJournal of Urology, VOL. 172, NO. 5, (1792-1799), Online publication date: 1-Nov-2004.Feifer A, Fleshner N and Klotz L (2018) Analytical Accuracy and Reliability of Commonly Used Nutritional Supplements in Prostate DiseaseJournal of Urology, VOL. 168, NO. 1, (150-154), Online publication date: 1-Jul-2002. Volume 163Issue 5May 2000Page: 1408-1412 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsurologic diseasesprostatic hyperplasiamedicine, herbalprostateMetricsAuthor Information GLENN S. GERBER More articles by this author Expand All Advertisement PDF downloadLoading ...